Trial advancement is a minor positive but carries no new data; look for initial safety/imaging data in late 2026 as the next catalyst. The 20-F (filed March 2026) provides the financial baseline for cash runway context.
Price Chart
Executive Summary
Molecular Partners announced the first patients have been dosed in a Phase 1/2a trial of MP0712, a DLL3-targeting Radio-DARPin carrying lead-212, for small cell lung cancer. This marks the clinical advancement of its lead Radio-DARPin candidate but remains an early-stage, binary catalyst event with no efficacy data yet.
Key Facts
- First patients dosed in US multicenter Phase 1/2a study of DLL3-targeting Radio-DARPin MP0712 (212Pb-labeled).
- Cohort 1 fully recruited; patients moving to repeat dosing.
- Five sites actively recruiting in the US; additional sites planned to open in 2026.
- Initial data expected within the coming months; comprehensive safety/efficacy dataset expected in 2027.
- DLL3 is present in >85% of SCLC tumors; low expression in healthy tissue.
- Program uses a matched-pair diagnostic/therapeutic approach with 203Pb-labeled imaging agent.
- Study contains up to four dose levels (ClinicalTrials.gov: NCT07278479).
Financial Impact
No financial figures disclosed; pre-revenue clinical-stage biotech. Cash runway referenced in forward-looking statements but no specific dollar amount provided.
Risk Factors
- Phase 1/2a safety/efficacy data may not support further development.
- Alpha-radiotherapy toxicity risks (bone marrow, off-target).
- Very early-stage trial; binary outcome risk high.
- Competing DLL3-targeted therapies (e.g., Amgen's tarlatamab) already in later stages.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-004433 |
| Document: f6k_070226.htm | 0001171843-26-004433 |
| Document: 0001171843-26-004433-index-headers.html | 0001171843-26-004433 |
| Document: 0001171843-26-004433-index.html | 0001171843-26-004433 |
| Document: 0001171843-26-004433.txt | 0001171843-26-004433 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 25, 2026 9w ago | 6-K | $4.38 $3.99 | ▼ −8.90% | ▼ −10.15% | $3.59 (−18.04%) |
Jul 20, 2026 14w ago | 6-K | $4.00 $4.25 | ▲ +6.25% | ▲ +2.13% | $3.59 (−10.25%) |
Jul 16, 2026 14w ago | Press Release | $4.10 $4.21 | ▲ +2.68% | ▼ −0.93% | $3.59 (−12.44%) |
Jul 6, 2026 16w ago | Press Release | $4.00 $3.93 | ▼ −1.75% | ▼ −1.18% | $3.59 (−10.25%) |
Jul 2, 2026 16w ago | 6-K | $3.98 $3.93 | ▼ −1.26% | ▼ −0.84% | $3.59 (−9.80%) |
Jul 2, 2026 16w ago | Press Release | $3.98 $3.93 | ▼ −1.26% | ▼ −0.84% | $3.59 (−9.80%) |
Jun 1, 2026 21w ago | 6-K | $3.95 $3.87 | ▼ −2.03% | ▼ −0.73% | $3.59 (−9.11%) |
May 12, 2026 24w ago | 6-K | $4.00 $3.71 | ▼ −7.25% | ▼ −6.64% | $3.59 (−10.25%) |
May 1, 2026 25w ago | Press Release | $4.24 $3.95 | ▼ −6.84% | ▼ −12.12% | $3.59 (−15.33%) |
Mar 30, 2026 30w ago | 6-K | $3.93 $4.28 | ▲ +8.91% | ▼ −3.69% | $3.59 (−8.65%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers